- 11 December 2012 BTG plc: Appointment of Non-executive Director
- 11 December 2012 BTG plc: US FDA approves expanded ZYTIGA® indication for treatment of metastatic castration-resistant prostate cancer
- 20 November 2012 BTG plc: Janssen announces that ZYTIGA® has received a positive opinion in the EU for treating chemo-naïve mCRPC patients
- 19 November 2012 Full data from pivotal Phase III trials of Varisolve® PEM presented at the 26th Annual Congress of the American College of Phlebology
- 08 November 2012 BTG plc: Interim Results
- 03 October 2012 BTG plc: Close Period Update
- 17 September 2012 BTG to present at the UBS Global Life Sciences Conference
- 10 September 2012 BTG to present at the Bank of America Merrill Lynch Global Healthcare Conference
- 05 September 2012 CMS grants new prospective reimbursement for Voraxaze®
- 08 August 2012 BTG Announces Data from Phase IIb Study of AZD9773
- 17 July 2012 BTG plc: Interim Management Statement
- 12 June 2012 BTG plc: Applications submitted to FDA and EMA for approval of Lemtrada™ (alemtuzumab) for Multiple Sclerosis
- 04 June 2012 BTG announces data presentation on Voraxaze® (glucarpidase) at the American Society of Clinical Oncology Annual Meeting
- 25 May 2012 BTG to present at the Jefferies Global Healthcare Conference
- 21 May 2012 BTG plc: Final Results
- 30 April 2012 Voraxaze® (glucarpidase) Launched in the US
- 23 April 2012 BTG Announces Positive Results from Second US Pivotal Phase III Trial of Varisolve®
- 04 April 2012 BTG plc: Close Period Update
- 28 March 2012 DigiFab® 40 mg/vial digoxin immune Fab, Powder for solution for infusion Launched in the UK
- 08 March 2012 BTG plc: ZYTIGA® (abiraterone acetate) second Phase III trial unblinded
- 20 February 2012 BTG to present at the Citi Global Health Care Conference
- 14 February 2012 BTG plc: Directorate Change Amendment
- 30 January 2012 BTG Announces Positive Data from First US Phase III Trial of Varisolve®
- 25 January 2012 BTG plc: Interim Management Statement
- 18 January 2012 BTG plc: Voraxaze® (glucarpidase) receives US regulatory approval
- 11 January 2012 BTG to present at the 30th Annual J.P. Morgan Healthcare Conference
Investors
Press Releases
Please find below a list of our press releases, organised in chronological order.
- 12 April 2013 BTG plc: Varisolve® NDA accepted for full review by FDA
- 04 April 2013 BTG plc: Close Period Update
- 21 February 2013 BTG to Present at the Citi Global Healthcare Conference
- 04 February 2013 BTG plc: Varisolve® NDA submitted to the FDA
- 31 January 2013 BTG plc: Interim Management Statement
- 07 January 2013 BTG to present at the 31st Annual J.P. Morgan Healthcare Conference
- 07 December 2011 BTG plc: Voraxaze® (glucarpidase) licensed to Ohara Pharmaceuticals in Japan
- 17 November 2011 BTG plc: Interim Results
- 11 November 2011 BTG plc: Garry Watts to succeed Dr John Brown as non-executive Chairman
- 01 November 2011 BTG plc: Directorate Change
- 05 October 2011 BTG plc: Close Period Update
- 20 September 2011 BTG plc: FDA accepts Biologics License Application file for Voraxaze® (glucarpidase) and grants Priority Review
- 07 September 2011 BTG plc: ZYTIGA™ (abiraterone acetate) approved in the EU
- 20 July 2011 BTG plc: Annual General Meeting and Interim Management Statement
- 11 July 2011 BTG plc: Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada™) in Multiple Sclerosis Reported
- 06 July 2011 BTG Acquires US Marketing Rights to Wellstat’s Investigational Antidote for 5-FU Overexposure
- 25 May 2011 BTG plc: Final Results
- 13 May 2011 BTG plc: AstraZeneca ends CM-3 development and option agreement
- 03 May 2011 BTG plc: ZYTIGA™ (abiraterone acetate) Approved in the US
- 05 April 2011 BTG plc: Close Period Update
- 11 March 2011 BTG plc: DEFEND-1 study of otelixizumab in type 1 diabetes did not meet primary endpoint
- 28 January 2011 Offer Update: Admission of New BTG Shares
- 27 January 2011 Offer Update: Scheme Effective
- 27 January 2011 BTG plc: Interim Management Statement
- 24 January 2011 Offer Update: Court sanction of the Scheme of Arrangement and timetable update
- 06 January 2011 Offer Update: Result of BTG Shareholder Meeting
- 06 January 2011 BTG to present at the J.P. Morgan Annual Healthcare Conference
- 21 December 2010 BTG plc: New Drug Application Submitted in the US and Marketing Authorisation Application Filed in the EU for Abiraterone Acetate
- 10 December 2010 Offer update: Posting of Scheme Document
- 29 November 2010 BTG plc: Appointment of Non-executive Director
- 19 November 2010 Recommended acquisition by BTG plc of Biocompatibles International plc
- 04 November 2010 BTG plc: Interim Results
- 25 October 2010 BTG plc: AstraZeneca initiates Phase IIb study for AZD9773 (CytoFab™) as a treatment for severe sepsis
- 15 October 2010 BTG plc: Genzyme reports positive data on alemtuzumab
- 16 September 2010 BTG plc: First Varisolve® US Phase III Trial Initiated
- 10 September 2010 BTG plc: Abiraterone Acetate Meets Pre-Determined Criteria in Metastatic Prostate Cancer Study
- 31 August 2010 BTG plc: Agreement with Nycomed US Inc.
- 13 July 2010 BTG plc: Annual General Meeting and Interim Management Statement
- 21 May 2010 BTG plc: Preliminary Results
- 01 April 2010 BTG plc: Close Period Update
- 04 February 2010 BTG Receives First European Regulatory Approval for DigiFab™
- 21 January 2010 BTG Commences Phase IIa Study of Pleneva™ for Multiple Sclerosis
- 21 January 2010 BTG plc: Interim Management Statement
- 18 December 2009 BTG Licenses ReGel® to Allergan for use in diseases of the eye
- 05 November 2009 BTG plc: Interim Results
- 24 September 2009 BTG plc: Campath® Meets Primary Endpoint in Phase III Combination Therapy Trial for Chronic Lymphocytic Leukemia
- 28 August 2009 BTG Sells HySolv™ Technology to Major Pharmaceutical Company
- 17 August 2009 BTG Collaborator Onyx Gains Approval to Progress Oncology Compound into Clinical Development
- 29 July 2009 BTG plc: AstraZeneca to Progress CytoFab™ into Phase IIb Study
- 15 July 2009 BTG plc: Annual General Meeting and Interim Management Statement
- 14 May 2009 BTG plc: Preliminary Results
- 02 April 2009 BTG plc: Close Period Update
- 22 January 2009 BTG plc: Interim Management Statement
- 04 December 2008 BTG plc: Completion of the Acquisition of Protherics PLC
- 20 November 2008 BTG Licensee Cougar Biotechnology Initiates Phase I/II Trial of CB7630 (Abiraterone Acetate) in Advanced Breast Cancer
- 12 November 2008 BTG plc: Interim Results for the Six Months Ended 30 September 2008
- 07 November 2008 Full Results of Varisolve® US Phase II Safety Study to be Presented at ACP
- 07 November 2008 BTG licenses novel anticancer compound to Onyx Pharmaceuticals
- 05 November 2008 BTG plc: Result of EGM
- 28 October 2008 BTG plc to Announce its Interim Results on 12 November 2008
- 23 October 2008 BTG plc: Final Phase II Results of Campath® Multiple Sclerosis Study Published
- 17 October 2008 BTG plc ("BTG") and Protherics PLC ("PROTHERICS"): Offer Update - Intended Date of Posting of Offer Documents
- 17 October 2008 BTG plc ("BTG") and Protherics PLC ("PROTHERICS"): Offer Update - Posting of Scheme Document/Receipt of Letters of Intent
- 18 September 2008 18 September 2008: Recommended All Share Offer by BTG plc for Protherics plc
- 06 August 2008 BTG plc: Tolerx Initiates Dosing of Otelixizumab in a Phase III Clinical Trial in Type 1 Diabetes
- 22 July 2008 BTG plc: Study Shows Abiraterone Can Successfully Treat Aggressive, Chemotherapy-Resistant Prostate Cancer
- 16 July 2008 BTG plc: Annual General Meeting and Interim Management Statement
- 06 June 2008 BTG Reports Successful Completion of Treatments in Varisolve® US Phase II Safety Study
- 04 June 2008 BTG plc: Acquisition of Protez Pharmaceuticals by Novartis
- 19 May 2008 BTG plc: Preliminary Results for the Year Ended 31 March 2008
- 10 April 2008 BTG Reports Positive Results from First Study Investigating BGC20-0166 in Obstructive Sleep Apnoea Patients
- 02 April 2008 BTG plc: Close Period Update
- 17 March 2008 BTG plc: Positive Interim Report of Varisolve® Phase II Safety Study to be Presented at SIR 2008 Scientific Meeting
- 06 March 2008 BTG Initiates Clinical Study of Novel Multiple Sclerosis Treatment
- 30 January 2008 BTG plc Commences First Clinical Study of Novel Migraine Treatment
- 24 January 2008 BTG plc: Interim Management Statement
- 17 January 2008 Senexis Raises £3.7 Million from the Wellcome Trust and BTG to Further Develop its Small Molecule Alzheimer's Compounds
- 13 December 2007 BTG Completes Enrolment of Phase II Clinical Trial of BGC20-0582 for Head Lice Infestation
- 04 December 2007 BTG plc Appoints Dr John Brown as Chairman Designate
- 07 November 2007 BTG plc: Interim Results for the Six Months Ended 30 September 2007
- 24 October 2007 BTG Licensee Tolerx Forms Collaboration with GlaxoSmithKline to Develop and Commercialise TRX4
- 28 September 2007 BTG plc: Board Changes
- 28 September 2007 BTG plc: Close Period Update
- 26 September 2007 BTG plc: Campath® commences pivotal phase III trial in multiple sclerosis
- 20 September 2007 BTG plc: Campath® approved for first-line use in Adult Leukemia
- 18 July 2007 BTG plc: 2007 Annual General Meeting and Interim Management Statement
- 07 June 2007 BTG plc: Orphan Drug Status Granted for Anticancer Drug Plevitrexed
- 25 May 2007 Preliminary Results Statement
- 19 April 2007 BTG Signs Agreement with Novacea and KuDOS for AQ4N
- 13 April 2007 BTG Continues Physical Sciences Divestment Programme Granting Two Licenses to Technology Patents Worth Up to $46m
- 02 April 2007 BTG plc: Close Period Update
- 27 February 2007 BTG Licensee Cougar Biotechnology Presents Positive Data on Prostate Cancer Compound at ASCO Symposium
- 20 February 2007 BTG Acquires Novel Opioid Agonist for Post-Operative Pain Control from CLL Pharma
- 19 February 2007 New Chief Medical Officer for BTG
- 22 January 2007 BTG's Plevitrexed Shows Promising Efficacy and Tolerability in a Phase I/II study
- 22 December 2006 BTG licenses haemofiltration device patents to Fresenius Medical Care
- 13 December 2006 Results of European Phase III Randomised Controlled Trial Comparing Varisolve ® with Surgery or Sclerotherapy Published in Phlebology
- 12 December 2006 Genzyme reports Phase III data showing Campath® is superior to Chlorambucil as a first-line therapy in B-CLL
- 09 November 2006 BTG plc: Interim Results for the Six Months Ended 30 September 2006
- 17 October 2006 Strata Technology Partners Retained by BTG to Auction Rights to a Substantial OLED Patent Portfolio
- 27 September 2006 BTG Appoints Peter Chambré as Non-Executive Director
- 25 September 2006 BTG Completes Sale of RFID Patent Portfolio
- 17 August 2006 BTG Licensee TolerRx, Inc. Raises $35.6m to Develop TRX4; Phase III Pivotal Trial in Type 1 Diabetes Planned to Commence in 2006
- 16 August 2006 BTG Sells Online Navigation Tracking Patents
- 31 July 2006 BTG PLC: Notification of Major Interests in Shares
- 26 July 2006 BTG plc: Results of AGM
- 26 July 2006 BTG plc: 2006 AGM Statement
- 25 July 2006 BTG plc: Notification of Major Interests in Shares
- 17 July 2006 BTG PLC: Notification of Major Interests in Shares
- 12 July 2006 Annual Information Update 2006
- 04 July 2006 BTG PLC: Notification of Major Interests in Shares
- 28 June 2006 Directors' Interests in the Shares of BTG plc
- 27 June 2006 BTG PLC: Application to the London Stock Exchange
- 23 June 2006 Notification of Submission of Documents to the UK Listing Authority
- 19 June 2006 Directors’ Interests in the Shares of BTG plc
- 19 June 2006 BTG to commence US phase II clinical safety study of Varisolve®
- 05 June 2006 BTG PLC : Notification of Major Interests in Shares
- 25 May 2006 BTG reports preliminary results for the year ended 31 March 2006
- 08 May 2006 BTG plc: Notification Of Major Interests In Shares
- 31 March 2006 BTG plc: Close Period Update
- 31 March 2006 BTG Sells Teleshuttle Patent Rights To Twintech E.U.
- 03 March 2006 BTG PLC : Notification of Major Interests in Shares
- 10 February 2006 BTG Appoints Piper Jaffray as Joint Financial Adviser and Joint Broker
- 06 February 2006 BTG Grants QRSciences Option to Acquire NQR Patents
-
02 February 2006
BTG Licenses Alzheimer's Compounds To Senexis And Co-Invests
£1 Million With The Wellcome Trust - 27 January 2006 BTG Licenses Analgesic Compounds from Asterand
- 15 December 2005 BTG Initiates Proof of Mechanism Clinical Study for its Novel Drug Therapy for Obstructive Sleep Apnoea
- 24 November 2005 Directors' Interests in the Shares of BTG plc
- 17 November 2005 Directors' Interests in the shares of BTG plc
- 10 November 2005 BTG plc: Interim Results
- 07 November 2005 BTG plc Releases Financial Statement Information For The Year to 31 March 2005 Restated Under IFRS
- 10 October 2005 BTG Licenses Barnes & Noble to its Online Navigation Tracking Patents
- 03 October 2005 BTG plc: Close Period Update and sale of RFID patents
- 19 September 2005 BTG plc: Campath® Progress and Date for Interim Results and Pipeline Update
- 05 September 2005 BTG PLC: Notification of Major Interests in Shares
- 29 August 2005 BTG and Collegium Pharmaceutical to Develop a Modified Release Asthma Product
- 15 August 2005 BTG Licenses Fundamental Online Navigation Tracking Patents to Netflix
- 28 July 2005 BTG PLC: 2005 Annual General Meeting
- 13 July 2005 BTG plc: Varisolve® given FDA approval to recommence US clinical trials
- 04 July 2005 Directors' Interests in the shares of BTG plc
- 28 June 2005 BTG plc: Notification of Submission of Documents to the UK Listing Authority
- 28 June 2005 Notification of Submission of Documents to the UK Listing Authority
- 24 June 2005 BTG plc: Publication of positive data from TRX4 type 1 diabetes study
- 26 May 2005 Directors' Interests in the shares of BTG plc
- 26 May 2005 BTG plc appoints Christine Soden as Chief Financial Officer
- 26 May 2005 BTG plc: Preliminary Results and Strategic Review
- 26 May 2005 BTG presents a live audio webcast to announce Preliminary results for the year ended 31 March 2005
- 23 May 2005 BTG PLC: Notification of Major Interests in Shares
- 19 May 2005 BTG settles two-part hip cup litigation
- 11 May 2005 BTG PLC: Notification of Major Interests in Shares
- 10 May 2005 BTG plc: Close Period Statement - Update
- 28 April 2005 BTG PLC : Notification of Major Interests In shares
- 21 April 2005 BTG plc: Update on Varisolve®
- 07 April 2005 BTG PLC: Notification of Major Interests in Shares
- 01 April 2005 BTG plc: CLOSE PERIOD UPDATE
- 09 February 2005 Statement regarding share price movement
- 27 January 2005 Update on Varisolve®
Keep up to date
You can keep up to date with our news by subscribing to our email alerts. Alternatively keep up to date with changes to our website by subscribing to one of our news feeds.
Regulatory news
In addition to press releases we issue regulatory news to the London Stock Exchange.